P22 virus-like particles as an effective antigen delivery nanoplatform for cancer immunotherapy
- 1 April 2021
- journal article
- research article
- Published by Elsevier in Biomaterials
- Vol. 271, 120726
Abstract
No abstract availableKeywords
Funding Information
- Fundamental Research Funds for the Central Universities (ZB19100123, 31970873, 18JCZDJC33300)
- National Natural Science Foundation of China (ZB19100123, 31970873, 18JCZDJC33300)
- Natural Science Foundation of Tianjin Municipality (ZB19100123, 31970873, 18JCZDJC33300)
This publication has 62 references indexed in Scilit:
- Personalized vaccines for cancer immunotherapyScience, 2018
- Towards personalized, tumour-specific, therapeutic vaccines for cancerNature Reviews Immunology, 2017
- Personalized T cell-mediated cancer immunotherapy: progress and challengesCurrent Opinion in Biotechnology, 2017
- Designer vaccine nanodiscs for personalized cancer immunotherapyNature Materials, 2016
- Neoantigen landscape dynamics during human melanoma–T cell interactionsNature, 2016
- Mutanome directed cancer immunotherapyCurrent Opinion in Immunology, 2016
- Neoantigens in cancer immunotherapyScience, 2015
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic ActivityCell, 2015
- Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemiaBlood, 2014
- Cancer immunotherapy comes of ageNature, 2011